Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.63 |
| ▸ | GABRP | O00591 | 1/20 | 0.59 |
| ▸ | GABRD | O14764 | 1/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.59 |
| ▸ | GABRE | P78334 | 1/20 | 0.59 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.59 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.59 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.59 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843412 | 0.89 | NR4A2 (0.63) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL28363236 | 0.86 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14089124 | 0.86 | NR4A2 (0.63) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL28265772 | 0.86 | GABRP (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1005283 | 0.85 | GABRP (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5213756 | 0.84 | NQO2 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2841773 | 0.84 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12501390 | 0.83 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13302316 | 0.82 | HTR7 (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27693237 | 0.81 | TNFSF11 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667216-B | (1H-indol-5-yl) acrylamide derivatives as inhibitors of TEAD proteins and HIPPO-YAP1/TAZ signaling cascades for the treatment of cancer | 赛诺菲 | 2025-02-18 | — | — | CN | disclosed |
| EP-4132907-B1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI SA (FR) | 2024-04-24 | — | — | EP | disclosed |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | SANOFI (FR) | 2023-05-04 | — | — | US | disclosed |
| EP-4132907-A1 | (1 H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2023-02-15 | — | — | EP | disclosed |
| CN-115667216-A | (1H-indol-5-yl) acrylamide derivatives as TEAD proteins and inhibitors of the HIPPO-YAP1/TAZ signaling cascade for the treatment of cancer | 赛诺菲 | 2023-01-31 | — | — | CN | disclosed |
| CN-105315262-A | Benzpyrole-3-carboxylic acid benzimidazole-2-methyl ester derivative and synthetic method thereof | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2016-02-10 | — | — | CN | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| EP-2125718-A2 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008113760-A2 | ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| WO-2007135380-A2 | ANTIPARASITIC COMPOUNDS AND COMPOSITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2007-11-29 | — | — | WO | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | NR4A2 169/4885GABRP 2459/4885GABRD 600/4885 |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | NR4A2 3961/4885GABRP 904/4885GABRD 2929/4885 |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | YAP1, YES1, TEAD1 | NR4A2 3198/4885GABRP 3281/4885GABRD 3244/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | NR4A2 21/4885GABRP 3686/4885GABRD 2412/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | NR4A2 21/4885GABRP 3686/4885GABRD 2412/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | NR4A2 26/4885GABRP 4007/4885GABRD 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.